BioNexus Q1 FY26 net loss narrows to $543,575; revenue drops 98.93% to $22,842

• BioNexus Gene Lab posted Q1 net loss attributable to common shareholders of USD 543,575, narrowing from a loss of USD 623,327 a year earlier; revenue plunged 98.93% to USD 22,842.
• Operating loss improved 12% to USD 540,490, while operating expenses fell 43% to USD 597,386.
• Chemrex revenue dropped 98.99% to USD 21,531, with gross margin swinging to -6.66% from 16.02% a year earlier due to direct manufacturing costs despite low production volumes.
• Cash and cash equivalents totaled USD 2.4 million at March 31, with management citing total liquidity above USD 4 million and saying current cash plus expected financing under a proposed up to USD 20 million ATM program should fund operations for at least 12 months.
• Company began deployment phase for VitaGuard MRD platform in ASEAN, holding a 15% equity stake in Fidelion and securing perpetual exclusive commercialization rights in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-003242), on May 15, 2026, and is solely responsible for the information contained therein.